Tessa Therapeutics today announced clinical data from the pilot stage of the ongoing Phase 2…
Continue ReadingTessa Therapeutics today announced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X,…
Continue ReadingTessa Therapeutics today announced that data from its ongoing autologous and allogeneic cell therapy studies…
Continue ReadingTessa Therapeutics today announced a collaboration agreement with the Agency for Science Technology and Research’s…
Continue Reading
Tessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being…
Continue Reading
Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of…
Continue Reading
Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…
Continue Reading
Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3)…
Continue Reading
Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME)…
Continue Reading